Never Miss a Potential Recovery Again

Sign up for Class
Action Alerts

Each year, class action lawsuits generate billions of dollars in settlement funds, but many shareholders fail to file a claim. Stay in the know regarding class action lawsuits by signing up for alerts.

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit. No spam will be sent to your email.

$720,134,300 in Total Settlement Funds Available. See if you qualify!Find Out More

We Give Shareholders A Voice.

The market fluctuates, but we don’t. We give you straight answers from real attorneys who have spent decades helping shareholders protect their investments and recover their losses.

Settlements

$47.5 Million

QuantumScape Corporation

$24.6 Million

Loma Negra Industrial Argentina Sociedad Argentina

$14 Million

Corcept Therapeutics Incorporated

$9.5 Million

Babcock & Wilcox Enterprises, Inc.

$40 Million

U.S. Steel

$7 Million

Aqua Metals, Inc.

$7.025 Million

WideOpenWest, Inc.

$8.25 Million

Helios and Matheson Analytics Inc.

$13.85 Million

Illumina, Inc.

$14.5 Million

Avon Products Inc.

I think you’ve done a superb job and I really appreciate the way this case was handled.

The Honorable Ronald B. Rubin in Teoh v. Ferrantino, C.A. No. 356627 (Cir. Ct. for Montgomery Cnty., MD 2012)

…a model for how [the] great legal profession should conduct itself.

Justice Timothy S. Driscoll in Grossman v. State Bancorp, Inc., Index No. 600469/2011 (N.Y. Sup. Ct. Nassau Cnty. Nov. 29, 2011)

I find the firm to be well-qualified to serve as Lead Counsel.

The Honorable Andrew L. Carter, Jr. In Snyder v. Baozun Inc., No. 1:19-CV-11290 (S.D.N.Y. Sept. 8, 2020)

In appointing the Firm Lead Counsel, the Honorable Analisa Torres noted our “extensive experience” in securities litigation.

White Pine Invs. v. CVR Ref., LP, No. 20 CIV. 2863 (S.D.N.Y. Jan. 5, 2021)

Class Counsel have demonstrated that they are skilled in this area of the law and therefore adequate to represent the Settlement Class as well.

Furthermore, with the increasing importance of compliance and risk management, kyc for law firms has become an essential component of legal services.

The Honorable Barry Ted Moskowitz in In re Regulus Therapeutics Inc. Sec. Litig., No. 3:17-CV-182-BTM-RBB (S.D. Cal. Oct. 30, 2020)

Who We Are

1
1
1
1
1
1

We're here for you

Find an Attorney

Required Field

Coin Image

Don't hesitate

Find a Case

Upcoming Deadlines

Investors interested in taking an active role in litigation have a limited time to petition the court for appointment as lead plaintiff. If you are interested in acting as a lead plaintiff, submit your transactions before the deadline, and our analysts will calculate your losses. Don't wait till the last minute- discuss your options today.
View All Deadlines

2

Days Left

SUI

Sun Communities, Inc.

Deadline

February 10 2025

Class Period

2/28/19 - 9/24/24

Allegations

According to the complaint, defendants provided investors with material information concerning SUI’s accounting practices and internal control over financial reporting. On September 24, 2024, after market close, an investment research report emerged calling into question the integrity of SUI’s Board and the integrity of the Company’s governance, controls, and financial disclosures. Investors and analysts reacted immediately to SUI’s revelation. The price of SUI’s common stock declined dramatically. From a closing market price of $139.10 per share on September 24, 2024, SUI’s stock price fell to a low of $137.48 per share on September 25, 2024.

Class Period

2/28/19 - 9/24/24

Deadline

February 10 2025

Learn More

2

Days Left

SAVA

Cassava Sciences, Inc.

Deadline

February 10 2025

Class Period

2/7/24 - 11/24/24

Allegations

According to the complaint, defendants provided investors with material information concerning Cassava’s leading drug candidate, simufilam. Defendants’ statements included, among other things, clear confidence in simufilam’s ability to treat Alzheimer’s Disease. On November 25, 2024, Cassava released topline results for the first of its two ongoing Phase 3 studies on simufilam, the “ReThink-ALZ” study. The results indicated that simufilam failed to meet each of the pre-specified primary, secondary, and exploratory endpoints; in sum, simufilam failed to outperform the placebo. Following this news, the price of Cassava’s common stock declined dramatically. From a closing market price of $26.48 per share on November 22, 2024, Cassava’s stock price fell to $4.30 per share on November 25, 2024, a decline of about 83.76% in the span of just a single day.

Class Period

2/7/24 - 11/24/24

Deadline

February 10 2025

Learn More

6

Days Left

MGPI

MGP Ingredients, Inc.

Deadline

February 14 2025

Class Period

5/4/23 - 10/30/24

Allegations

According to the filed complaint, throughout the class period, defendants made materially false and/or misleading statements, and failed to disclose material adverse facts about MGPI's business, operations, and prospects. Specifically, defendants repeatedly touted a strong demand and “normal” inventory levels in brown goods (i.e., American whiskies and tequila), when in fact there had been a slowdown in consumption and oversupply in their products. Worse, defendants had assured investors that they were positioned differently than their competitors, and that this was a non-issue, because MGPI had already taken steps to mitigate the risk, when in fact it had not.

Class Period

5/4/23 - 10/30/24

Deadline

February 14 2025

Learn More

10

Days Left

APLT

Applied Therapeutics, Inc.

Deadline

February 18 2025

Class Period

1/3/24 - 12/2/24

Allegations

According to the complaint, on November 27, 2024, Applied Therapeutics issued a press release announcing that it had received a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, the Company’s lead drug candidate. The CRL indicated that the FDA completed its review of the application and determined that it was unable to approve the NDA in its current form citing deficiencies in the clinical application. Following this news, the price of Applied Therapeutics’ common stock declined dramatically. From a closing market price of $10.21 per share on November 26, 2024, Applied Therapeutics’ stock price fell to $8.57 per share on November 27, 2024 before falling further to $2.03 on November 29, 2024 and $1.75 per share on December 2, 2024, a total decline of more than 80%. After market hours on December 2, 2024, Applied Therapeutics disclosed it received a “warning letter” from the FDA referring to the clinical trial issues underlying the CRL. Applied Therapeutics’ disclosure of the “warning letter” prompted a further decline in the stock price as investors discovered the seriousness and severity of the Company’s clinical trial errors. From a closing market price of $1.75 per share on December 2, 2024, Applied Therapeutics’ stock price fell to $1.69 per share on December 3, 2024 before falling further to $1.38 per share on December 4, 2024 and $1.29 per share on December 5, 2024.

Class Period

1/3/24 - 12/2/24

Deadline

February 18 2025

Learn More

10

Days Left

KSPI

Joint Stock Company Kaspi.kz

Deadline

February 18 2025

Class Period

1/19/24 - 9/19/24

Allegations

(1) Joint Stock Company Kaspi.kz continued doing business with Russian entities, and also providing services to Russian citizens, after Russia’s 2022 invasion of Ukraine, thereby exposing the Company to the undisclosed risk of sanctions; (2) the Company engaged in undisclosed related party transactions; (3) certain of the Company’s executives have links to reputed criminals; and (4) as a result, defendants’ statements about Joint Stock Company Kaspi.kz’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

1/19/24 - 9/19/24

Deadline

February 18 2025

Learn More

13

Days Left

AZN

AstraZeneca PLC

Deadline

February 21 2025

Class Period

2/23/22 - 12/17/24

Allegations

(1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca understated its legal risks; (4) the foregoing, once revealed, could materially harm AstraZeneca’s business activities in China; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

2/23/22 - 12/17/24

Deadline

February 21 2025

Learn More

13

Days Left

CPRI

Capri Holdings Limited

Deadline

February 21 2025

Class Period

8/10/23 - 10/24/24

Allegations

(a) the accessible luxury handbag market is a distinct and well-defined market within the overall handbag market and understood as such by the Individual defendants, as well as by other Capri and Tapestry executives; (b) Capri and Tapestry maintained analogous production facilities and supply chains for their accessible luxury handbags that were distinct from the production facilities and supply chains used to manufacture luxury or mass market handbags, confirming that the accessible luxury handbag market is distinct from the mass market and luxury handbag markets; (c) Capri and Tapestry internally considered Coach and Michael Kors to be each other’s closest and most direct competitors; (d) conversely, Capri and Tapestry did not internally consider their handbag brands to be in direct competition with luxury handbags or mass market handbags; (e) a primary internal rationale for the Capri Acquisition, the acquisition of Capri by Tapestry, was to consolidate prevalent brands within the accessible luxury handbag market so as to reduce competition, increase prices, improve profit margins, and reduce consumer choice within that market; and (f) as a result of (a)-(e) above, the risk of adverse regulatory actions and/or the Capri Acquisition being blocked was materially higher than represented by defendants.

Class Period

8/10/23 - 10/24/24

Deadline

February 21 2025

Learn More

16

Days Left

RIG

Transocean Ltd.

Deadline

February 24 2025

Class Period

10/31/23 - 9/2/24

Allegations

(1) the oil rigs Discoverer Inspiration and Development Driller III were considered non-strategic assets; (2) the Company’s recorded asset valuations were overstated; (3) as a result, the Company would take nearly twice the vessels’ sale price in impairment if sold; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

10/31/23 - 9/2/24

Deadline

February 24 2025

Learn More

16

Days Left

CRBU

Caribou Biosciences, Inc.

Deadline

February 24 2025

Class Period

7/14/23 - 7/16/24

Allegations

(i) they had overstated CB-010’s safety, efficacy, and durability relative to approved autologous CAR-T cell therapies in treating patients with r/r B-NHL and/or LBCL, as well as CB-010’s overall clinical results and commercial prospects; (ii) Caribou was at significant risk of having insufficient cash, liquidity, and/or other capital to fund its current business operations, including preclinical research activities associated with the allogeneic CAR-NK platform; (iii) all the foregoing was likely to have a significant negative impact on Caribou’s business and operations; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

7/14/23 - 7/16/24

Deadline

February 24 2025

Learn More

17

Days Left

NXT

Nextracker Inc.

Deadline

February 25 2025

Class Period

2/1/24 - 8/1/24

Allegations

(a) the impact of project delays on Nextracker’s business, financial results, and prospects was far more severe than represented to investors; (b) permitting and interconnection delays had materially impaired Nextracker’s ability to convert backlog into revenue at historical conversion rates; (c) Nextracker had been unable to offset the negative impact from project delays through increased client demand and the purported ability to pull forward its other projects in the manner represented by defendants; (d) Nextracker did not possess the competitive advantages which purportedly shielded it from industry-wide headwinds or the ability to effectively offset the adverse effects of project delays as claimed by defendants; and (e) as a result of (a)-(d) above, defendants lacked a reasonable basis for their positive statements about Nextracker’s business, financial results, and prospects.

Class Period

2/1/24 - 8/1/24

Deadline

February 25 2025

Learn More

24

Days Left

RVNC

Revance Therapeutics, Inc.

Deadline

March 4 2025

Class Period

2/29/24 - 12/6/24

Allegations

(i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance “the exclusive right to import, market, promote, sell and distribute Teoxane’s line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (iii) all the foregoing increased the risk that the tender offer would be delayed and/or amended; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

2/29/24 - 12/6/24

Deadline

March 4 2025

Learn More

30

Days Left

REGN

Regeneron Pharmaceuticals, Inc.

Deadline

March 10 2025

Class Period

11/2/23 - 10/30/24

Allegations

(1) Regeneron paid credit card fees to distributors on the condition that distributors did not charge, one of the Company’s primary products, Eylea customers more to use a credit card; (2) these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) as a result, Regeneron offered a price concession that lowered Eylea’s selling price; (4) because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron’s price concessions provided a competitive advantage; (5) as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; (6) by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (7) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/2/23 - 10/30/24

Deadline

March 10 2025

Learn More

30

Days Left

BIOA

BioAge Labs, Inc.

Deadline

March 10 2025

Class Period

This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024.

Allegations

According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.

Class Period

This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024.

Deadline

March 10 2025

Learn More

30

Days Left

MU

Micron Technology, Inc.

Deadline

March 10 2025

Class Period

9/28/23 - 12/18/24

Allegations

(i) demand for Micron’s products in consumer markets, especially the Company’s NAND products, had significantly deteriorated; (ii) accordingly, defendants had overstated the extent to which demand for Micron’s products had recovered, particularly in consumer markets and for its NAND products, and/or had overstated the sustainability of demand for such products, as well as the normalization of inventory for such products; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

9/28/23 - 12/18/24

Deadline

March 10 2025

Learn More

34

Days Left

PCRX

Pacira BioSciences, Inc.

Deadline

March 14 2025

Class Period

8/2/23 - 8/8/24

Allegations

According to the complaint, on August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement. Pacira disclosed that the court “found that the company’s U.S. Patent No. 11,033,495 (the ‘495 patent) is not valid,” and, thus, eVenus is not infringing on anything. Pacira’s ‘495 patent is for Exparel, which is the main source of growth for the Company, encapsulating roughly 80% of its revenue. Analysts have noted that the invalidity of the ‘495 patent calls into question the validity of the Company’s other patents, potentially resulting in more generic entrants into the market and increased litigation expenses moving forward. Following this news, Pacira’s common stock declined dramatically. From a closing market price of $22.36 per share on August 8, 2024, Pacira’s stock price fell to a low of $11.70 per share on August 9, 2024, a decline of over 47% in a single day.

Class Period

8/2/23 - 8/8/24

Deadline

March 14 2025

Learn More

38

Days Left

XYZ

Block, Inc.

Deadline

March 18 2025

Class Period

2/26/20 - 4/30/24

Allegations

(a) Block had engaged in widespread and years-long compliance lapses at Square and Cash App, including by failing to conduct basic due diligence regarding its customers’ identities or the nature of customer transactions so as to prevent the platforms from being used for illegal or illicit activities; (b) Block had effectively created a haven for widespread illegal and illicit activities on its Square and Cash App platforms by imposing minimal obligations on customers seeking to open accounts, transact, and deposit or withdraw funds; encouraging the use of bitcoin; and pressuring the Company’s banking partners to forgo ordinary know your customer due diligence activities; (c) thousands of transactions on Square and Cash App were made in connection with a wide variety of illegal and illicit activities, including, inter alia, money laundering, child sexual abuse, sex trafficking, drug trafficking, terrorism financing, contract killings, and illicit payments to entities and persons subject to economic sanctions; (d) Block allowed its customers to withdraw funds even after the accounts had been flagged for potentially illegal or illicit activities; (e) Block customers could open up multiple accounts using fake identities in order to engage in illegal or illicit activities; (e) Block customers could open up multiple accounts using fake identities in order to engage in illegal or illicit activities; (f) Block’s senior leadership and the Board had failed to correct identified compliance deficiencies despite numerous red flags, internal employee reports of deficiencies, and customer complaints; (g) Block’s Cash App user metrics had been artificially inflated through the use of fake accounts and the ability of criminals and other bad actors to open multiple accounts; and (h), as a result of (a)-(g) above, Block was subject to a material, undisclosed risk of its conduct being exposed, thereby exposing the Company to reputational harm, adverse regulatory actions, the loss of business activity, and adverse impacts to the Company’s operations and financial results.

Class Period

2/26/20 - 4/30/24

Deadline

March 18 2025

Learn More

38

Days Left

IIPR

Innovative Industrial Properties, Inc.

Deadline

March 18 2025

Class Period

2/27/24 - 12/19/24

Allegations

(i) IIPR was experiencing significant declines in rent and property-management fees in connection with certain customer leases; (ii) the foregoing would likely impair the Company’s ability to maintain funds from operations and revenue growth; (iii) accordingly, IIPR’s leasing operations were less profitable than the Company had represented to investors; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

2/27/24 - 12/19/24

Deadline

March 18 2025

Learn More

38

Days Left

FTAI

FTAI Aviation Ltd.

Deadline

March 18 2025

Class Period

7/23/24 - 1/15/25

Allegations

(1) the Company reported one-time engine sales as maintenance repair & overhaul revenue when FTAI only performs limited repair and maintenance work on the engine assets sold; (2) FTAI presents whole engine sales as individual module sales, thereby overstating sales and demand; (3) the Company depreciates engines that are not on lease, which misleadingly lowers the reported cost of goods sold and inflates EBITDA; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

7/23/24 - 1/15/25

Deadline

March 18 2025

Learn More

44

Days Left

CROX

Crocs, Inc.

Deadline

March 24 2025

Class Period

11/3/22 - 10/28/24

Allegations

(1) the nature and sustainability of footwear brand, HEYDUDE’s revenue growth by concealing that 2022 revenue growth was driven, in large part, by the Company’s efforts to stock third-party wholesalers and retailers following the February 2022 acquisition of HEYDUDE; (2) as the Company’s retail partners began to destock this excess inventory, waning product demand further negatively impacted the Company’s financial results; and (3) as a result, defendants’ representations about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Class Period

11/3/22 - 10/28/24

Deadline

March 24 2025

Learn More

45

Days Left

CDLX

Cardlytics, Inc.

Deadline

March 25 2025

Class Period

3/14/24 - 8/7/24

Allegations

(1) increasing consumer engagement led to an increase in consumer incentives; (2) the Company could not increase its billings commensurate with the increased consumer engagement; (3) as a result, there was a significant risk that its revenue growth would slow or decline; (4) the changes to Ads Decision Engine, which led to increased consumer engagement, led to the “under-delivery” of budgets and customers billing estimates; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

3/14/24 - 8/7/24

Deadline

March 25 2025

Learn More

45

Days Left

EPIX

ESSA Pharma Inc.

Deadline

March 25 2025

Class Period

12/12/23 - 10/31/24

Allegations

(i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (iii) the M-E Combination Study, a monotherapy and combination therapy for the treatment of prostate cancer, was unlikely to meet its prespecified Phase 2 primary endpoint; (iv) accordingly, defendants had overstated masofaniten’s clinical, regulatory, and commercial prospects; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

12/12/23 - 10/31/24

Deadline

March 25 2025

Learn More

45

Days Left

NVO

Novo Nordisk A/S

Deadline

March 25 2025

Class Period

11/2/22 - 12/19/24

Allegations

According to the complaint, on December 20, 2024, Novo issued a press release announcing the below-expected results of their “REDEFINE 1” trial, “a 68-week efficacy and safety trial investigating subcutaneous CagriSema.” The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo’s targeted expectation of at least 25% weight loss. The press release further indicated that participant patients were permitted to modify their own dosage during the trial and, as a result, only 57.3% of patients treated with CagriSema were on the highest dosage contemplated by the study. Following this news, Novo’s stock price fell by $18.44 per share to close at $85.00 per share.

Class Period

11/2/22 - 12/19/24

Deadline

March 25 2025

Learn More

51

Days Left

IAS

Integral Ad Science Holding Corp.

Deadline

March 31 2025

Class Period

3/2/23 - 2/27/24

Allegations

(i) IAS was experiencing a new material trend of increased competitive pricing pressures and as a result, IAS had been forced to cut prices to compensate for weakening demand and slowing revenue growth; (ii) IAS’s pricing function was no longer “favorable” and IAS could not sustain its pricing and drive price increases; (iii) pricing had become a key differentiator between IAS and its competitor necessary to close major renewals and new deals; (iv) the risks that competition “could result in increased pricing pressure” or “could put pressure on us to change our prices” had in fact transpired; and (v) as a result, the IAS’s public statements were materially false and misleading at all relevant times.

Class Period

3/2/23 - 2/27/24

Deadline

March 31 2025

Learn More

51

Days Left

GO

Grocery Outlet Holding Corp.

Deadline

March 31 2025

Class Period

11/7/23 - 5/7/24

Allegations

According to the complaint, after-market on May 7, 2024, Grocery Outlet announced its financial results for the first quarter of fiscal 2024, published significantly below-expectation guidance for the second quarter, and further reduced its guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on “unforeseen systems transition costs that surfaced at the end of the quarter” and the resulting “residual expense from our commission support program as we finish store physical inventory counts in the second quarter.” Following this news, Grocery Outlet’s stock price fell to $20.88 per share on May 8, 2024, a decline of about 19.38% in the span of just a single day.

Class Period

11/7/23 - 5/7/24

Deadline

March 31 2025

Learn More

51

Days Left

MODV

ModivCare Inc.

Deadline

March 31 2025

Class Period

11/3/22 - 9/15/24

Allegations

According to the filed complaint, defendants made false statements and/or concealed that certain contracts used in ModivCare’s NEMT segment caused the Company’s free cash flow to deteriorate and as a result, (1) contract renegotiations and pricing accommodations negatively impacted the Company’s adjusted EBITDA; (2) the Company had insufficient liquidity; and (3) defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/3/22 - 9/15/24

Deadline

March 31 2025

Learn More

51

Days Left

TIXT

TELUS International (Cda) Inc.

Deadline

March 31 2025

Class Period

2/16/23 - 8/1/24

Allegations

(1) the Company’s AI Data Solutions offerings required the cannibalization of its higher-margin offerings; (2) Telus International’s declining profitability was tied to the Company’s drive to develop AI capabilities; (3) Telus International’s shift toward AI put greater pressure on the Company’s margins than previously disclosed; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

2/16/23 - 8/1/24

Deadline

March 31 2025

Learn More

51

Days Left

WBA

Walgreens Boots Alliance, Inc.

Deadline

March 31 2025

Class Period

4/2/20 - 1/16/25

Allegations

(i) contrary to the Company’s purported commitment to improved regulatory compliance, Walgreens continued to engage in widespread violations of federal law governing the dispensation of prescription medication and reimbursement for the same; (ii) the foregoing conduct, when revealed, would subject Walgreens to a heightened risk of further regulatory scrutiny, civil liability, and reputational harm; (iii) Walgreens’ revenues from the sale of prescription medications were unsustainable to the extent that they derived from unlawful conduct; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

4/2/20 - 1/16/25

Deadline

March 31 2025

Learn More

51

Days Left

ARNC

Arconic Corporation

Deadline

March 31 2025

Class Period

This lawsuit is on behalf of a Class of all persons who sold publicly traded shares of Arconic common stock between April 19, 2022 and May 3, 2023, both dates inclusive.

Allegations

According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that defendants stated in Arconic’s quarterly and annual reports issued during the Class Period that Arconic’s share repurchase programs were “intended to comply with Rule 10b5-1,” which prohibits securities trading on the basis of material nonpublic information, and that all of Arconic’s share purchases “were made in compliance with Rule 10b-18,” which provides a safe harbor for share repurchases that meet certain criteria, but does not provide a safe harbor for insider trading or other violations of the federal securities laws. However, at the time those statements were made, Arconic had made share repurchases while in possession of material nonpublic information, and therefore Arconic’s share repurchase programs were not in compliance with Rule 10b5-1, and the share repurchases were not made in compliance with Rule 10b-18. Further, defendants stated that they were continuing with share repurchases. Inasmuch as the Company was restrained by law from buying back stock during active negotiations with Apollo, the defendants’ statements with respect to ongoing stock repurchases signaled to the market that there were no, and had been no, ongoing negotiations. Accordingly, when speaking about the stock repurchases, the defendants were obligated to disclose the whole truth – that they were in, or had been in, negotiations with Apollo.

Class Period

This lawsuit is on behalf of a Class of all persons who sold publicly traded shares of Arconic common stock between April 19, 2022 and May 3, 2023, both dates inclusive.

Deadline

March 31 2025

Learn More

52

Days Left

NEM

Newmont Corporation

Deadline

April 1 2025

Class Period

2/22/24 - 10/23/24

Allegations

According to the complaint, on October 23, 2024, Newmont published a press release announcing disappointing EBITDA third quarter 2024 highlights, in addition to decreases in production and increases in operating costs. In pertinent part, Newmont revealed that mining operations at its two Tier 1 assets would see lower production than originally guided with expectations of higher costs at these facilities. Following this news, Newmont’s stock price fell from a closing market price of $57.74 per share on October 23, 2024 to $49.25 per share on October 24, 2024.

Class Period

2/22/24 - 10/23/24

Deadline

April 1 2025

Learn More

58

Days Left

NMRA

Neumora Therapeutics, Inc.

Deadline

April 7 2025

Class Period

This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023.

Allegations

(1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn’s original Phase Two trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder, MDD, to show that Navacaprant, Neumora’s flagship therapeutic candidate, offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.

Class Period

This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023.

Deadline

April 7 2025

Learn More

58

Days Left

MPWR

Monolithic Power Systems Inc.

Deadline

April 7 2025

Class Period

2/8/24 - 11/8/24

Allegations

(a) Monolithic’s voltage regulator modules and power management integrated circuits were suffering from significant performance and quality control issues; (b) the defects listed in (a), above, had, in turn, negatively impacted the performance of certain products offered by the Company's largest customer, Nvidia, in which such products were used; (c) Monolithic had failed to adequately address and resolve known issues affecting the performance of the power management solutions the Company supplied to Nvidia; (d) Monolithic’s relationship with Nvidia had been irreparably damaged due to the significant performance and quality control.

Class Period

2/8/24 - 11/8/24

Deadline

April 7 2025

Learn More

58

Days Left

GSK

GSK plc

Deadline

April 7 2025

Class Period

2/5/20 - 8/14/22

Allegations

According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market “[b]ased on information available at the time and correspondence with regulators.” GSK also stated that it was “continuing with investigations into the potential source of NDMA.” Defendants also assured investors that “GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients,” findings that were “consistent with other ranitidine data published prior to 2019.” Finally, defendants claimed that they could not “quantify or reliably estimate the liability.” These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market.

Class Period

2/5/20 - 8/14/22

Deadline

April 7 2025

Learn More

News

Stay informed with the latest in settlement notices, case updates, publications, analyst reports, and more.
View All News

Learn More

Update In re Grab Holdings Limited Securities Litigation, Case No. 1:22-cv-02189-JLR
A settlement has been reached and was preliminarily approved on January 13, 2025. The settlement provides for the payment of $80 million to eligible class members. Co-lead plaintiff SLG Cloudbank Holdings, LLC alleged violations of §§ 11 and 15 of the Securities Act of 1933 and §§ 10(b), 14(a), and 20(a) of the Securities Exchange...Read more

February 7, 2025

Learn More

IIPR Out Millions After Major Tenant Defaults -- Lawsuits Follow
Investors’ hopes went up in smoke after Innovative Industrial Properties revealed one of its major tenants defaulted on its leases.  The news caused the Company’s stock price to tumble twenty-two percent overnight, prompting some investors to take legal action. Innovative Industrial Properties leases real estate to government-licensed cannabis companies.   Throughout 2024, Innovative boasted it was...Read more

February 5, 2025

Learn More

AML and Fraud Accusations Against Block Triggers Investor Lawsuit
State and federal authorities made explosive AML and fraud allegations against Block, the owner of Cash App.  Block paid out $255 million dollars in fines, shocking investors.  Some of those stunned investors are now suing the Company. Cash App – a popular banking app – was the target of a shocking short-seller investigation in February...Read more

February 1, 2025

Our World-Class Team

Levi & Korsinsky’s attorneys are admitted in over 40 state, federal, and appeal courts across the country. We have the specialized securities skills to achieve outstanding results, and our impressive variety of backgrounds means that we can go up against large companies of any kind and win. Our powerhouse attorneys have backgrounds in accounting, engineering, SEC enforcement, mathematics, regulatory analysis, international business, and prosecution, to name just a few. . .

View Attorneys